Granulocyte transfusion therapy: Randomization after all?

Haematologica

Volumn 94, Issue 12, 2009, Pages 1644-1648

  Drewniak, Agata ^a,b   Kuijpers, Taco W ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HETASTARCH; VORICONAZOLE;

ADD ON THERAPY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; APLASTIC ANEMIA; BACTERIAL INFECTION; BLOOD CELL COUNT; BLOOD DONOR; BLOODSTREAM INFECTION; BONE METABOLISM; BONE PAIN; CANDIDEMIA; CATARACTOGENESIS; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG SAFETY; EDITORIAL; FEVER; GRAFT VERSUS HOST REACTION; GRANULOCYTE; GRANULOCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LEUKAPHERESIS; LUNG COMPLICATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; SECONDARY PREVENTION; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOSIS;

ANEMIA, APLASTIC; BACTERIAL INFECTIONS; CLINICAL TRIALS, PHASE III AS TOPIC; GRANULOCYTES; HUMANS; LEUKOCYTE TRANSFUSION; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 73149124519     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013680     Document Type: Editorial

References (28)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Gerson SL, Talbot GH, Hurwitz S, Storm BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
3. Freireich EJ, Levin RH, Whang J, Carbone PP, Bronson W, Morse EE. The function and the fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic patients. Ann NY Acad Sci 1964;113:1081-9.
4. Herzig RH, Herzig GP, Graw RG Jr, Bull MI, Ray KK. Successful granulocyte transfusion therapy for Gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 1977;296:701-5.
5. Graw RG Jr, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to Gram-negative bacteria. N Engl J Med 1972;287:367-71.
6. Strauss RG. Therapeutic granulocyte transfusions in 1993. Blood 1993;81:1675-8.
7. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:1883-8.
8. Liles WC, Huang JE, Llewellyn C, Sen Gupta D, Price TH, Dale SC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997;37:182-7.
9. van de Wetering MD, Weggelaar N, Offringa M, Caron HN, Kuijpers TW. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. Eur J Cancer 2007; 43:2082-92.
10. Dale DC, Liles WC, Llewellyn C, Rodger E, Price TH. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion 1998;38:713-21.
11. Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica 2008;93:1058-67.
12. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994;84:3885-94.
13. Drewniak A, van Raam BJ, Geissler J, Tool AT, Mook OR, van den Berg TK, et al. Changes in gene expression of granulocytes during in vivo G-CSF/dexamethasone mobilization for transfusion purposes. Blood 2009;114:5979-98.
14. Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. Transfusion 2009;49:513-8.
15. Peters C. Granulocyte transfusions in neutropenic patients: beneficial effects proven? Vox Sang 2009;96:275-83.
16. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, et al. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004;101:2859-65.
17. Ofran Y, Avivi I, Oliven A, Oren I, Zuckerman T, Bonstein L, et al. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang 2007;93:363-9.
18. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica 2009;94:1661-68.
19. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
20. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000;95:3302-9.
21. Hubel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002;42:1414-21.
22. Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008;42:679-84.
23. Massey E, Paulus U, Doree C, Stanworth S. Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2009;CD005341.
24. Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, et al. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 2006;46:14-23.
25. Kerr JP, Liakopolou E, Brown J, Cronish JM, Fleming D, Massey E, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003;123: 114-8.
26. Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bombke B, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005;84:734-41.
27. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004;33:943-8.
28. Depalma L, Leitman SF, Carter CS, Gallin JI. Granulocyte transfusion therapy in a child with chronic granulomatous disease and multiple red cell alloantibodies. Transfusion 1989;29:421-3.